National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Understanding Cancer Series: Molecular Diagnostics
< Back to Main
In English     En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Slide 19  :  Lymphomas and Microarray Research <  >  

One of the first discoveries of cancer subtypes was in a blood cancer called diffuse large B cell lymphoma (the most common subtype of non-Hodgkin's lymphoma). Using a chip that contained fragments of 18,000 genes, researchers found two distinct cancer subtypes. These cancers looked the same under the microscope, but had different patterns of gene activity.

The subtypes were different in other ways, too. For one thing, they arose from different types of cells. Tumor cells of one cancer subtype arose from less differentiated ("younger") lymphocytes, while the other subtype arose from more differentiated ("older") lymphocytes.

There was also a survival difference between the two types. About 75 percent of the people with the "younger" subtype responded to chemotherapy, compared with only 25 percent of the people with the "older" subtype.

Lymphomas and Microarray Research

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov